EPISODE · Jun 25, 2025 · 20 MIN
2025 Biotech Markets & Immuno-Oncology Outlook
from PharmaTalkRadio · host Conference Forum
Summary:Mizuho Securities Analyst, Dr Graig Suvannavejh, joined the 2025 Immuno-Oncology 360º Summit to share an outlook on the IO biotech market, high-level thoughts on the IO space, and public IO company case studies to illustrate the market's perception of what's happening in IO. More specifically:The current tailwinds working for and headwinds working against investment in biotechThe increasing specialization of investors and lack of generalist investors The impacts of challenging and/or disappointing readouts after the first wave of checkpoint inhibitorsWhere investors are more positive on biotech, and reasons for optimism in coming pipelinesFor more information, visit IO360summit.com
What this episode covers
Summary:Mizuho Securities Analyst, Dr Graig Suvannavejh, joined the 2025 Immuno-Oncology 360º Summit to share an outlook on the IO biotech market, high-level thoughts on the IO space, and public IO company case studies to illustrate the market's perception of what's happening in IO. More specifically:The current tailwinds working for and headwinds working against investment in biotechThe increasing specialization of investors and lack of generalist investors The impacts of challenging and/or disappointing readouts after the first wave of checkpoint inhibitorsWhere investors are more positive on biotech, and reasons for optimism in coming pipelinesFor more information, visit IO360summit.com
NOW PLAYING
2025 Biotech Markets & Immuno-Oncology Outlook
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.